Organon Predicts Implanon Launch In 2005 Following "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to introduce the contraceptive sub-dermal implant in the first half of the year. In deeming Implanon "approvable," FDA did not request additional trials, Organon says. The product is expected to carry a maximum three-year indication upon approval.
You may also be interested in...
Organon’s Implanon Is First Single-Rod Implantable Contraceptive
The etonogestrel implant will be available in conjunction with launch of Organon’s physician training program by the end of August.
Organon’s Implanon Is First Single-Rod Implantable Contraceptive
The etonogestrel implant will be available in conjunction with launch of Organon’s physician training program by the end of August.
Depo-Provera "Black Box" Urges Limited Long-Term Use
Pfizer's injectable contraceptive should be used longer than two years "only if other birth control methods are inadequate," the "black box" states. Warning regarding bone loss is based on two five-year Phase IV studies in adolescents and adults.